Emergent BioSolutions News and Activities
Presence
Emergent BioSolutions develops and manufactures vaccines, biologics, and specialty medicines. It also provides contract development and manufacturing services for governments, healthcare organizations, and pharmaceutical companies.
Emergent BioSolutions products and services overview:
- Vaccines
- Biologics manufacturing
- Specialty medicines
- Medical countermeasures
- Drug development services
- Contract manufacturing
Revenue: ~$820 million
Employees: 1,100
Headquarters: Gaithersburg, United States (USA)
Emergent BioSolutions is one of the...
Emergent BioSolutions is a company listed under the stock ticker EBS (US).
Executives
View the org chart displaying its 20 main executives
Most searched biographies at Emergent BioSolutions
- Joseph Papa, Chief Executive Officer and Director
- Zsolt Harsanyi, Chairman of the Board
- Ronald Richard, Lead Independent Director
Popular executive movements at Emergent BioSolutions
- John Fowler has joined the company as Director (posted on March 4 2026).
Create your alert
to follow the executive moves at Emergent BioSolutions.
Pharmaceuticals
Emergent BioSolutions has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
- Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Emergent BioSolutions
- Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency | Emergent BioSolutions Inc.
- Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position | Emergent BioSolutions Inc.
- Emergent BioSolutions Reports Financial Results for Second Quarter 2023 | Emergent BioSolutions Inc.
- Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola | Emergent BioSolutions Inc.
- Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use | Emergent BioSolutions Inc.
- Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023 | Emergent BioSolutions Inc.
- Emergent BioSolutions Announces CEO Transition | Emergent BioSolutions Inc.
- Emergent BioSolutions Reports Financial Results For First Quarter 2023 | Emergent BioSolutions Inc.
- News | Emergent BioSolutions Inc.
- Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic | Emergent BioSolutions Inc.
- View more press releases Close
Social media about Emergent BioSolutions
- Emergent BioSolutions on Wikipedia, Google News & Yahoo Finance
- Emergent BioSolutions on LinkedIn, X (Twitter) & YouTube
